Paper Details

  1. Home
  2. Paper Details

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

Author: AlcindorThierry, AttiaSteven, BadalamentiGiuseppe, Ben-ShaharOsnat, BeveridgeRoberto Diaz, BlayJean-Yves, BurgessMelissa, ChangHua, ChawlaSant, ChenJames L, ChevreauChristine, ChmielowskiBartosz, DavisElizabeth J, DeshpandeHari, DicksonMark A, DuffaudFlorence, EliasAnthony, ErikssonMikael, ForscherCharles, GanjooKristen N, Garcia Del MuroXavier, GonzalezAnna Estival, GounderMrinal M, GrignaniGiovanni, GröschelStefan, GötzeKatharina, HartnerLee, HatcherHelen, HerráezAntonio Casado, ItalianoAntoine, JonesRobin L, KasperBernd, KauffmanMichael G, LandesmanYosef, LapeireLore, Le CesneAxel, LeeAlexander, LiLingling, LiuJianjun, LoggersElizabeth T, Martin-BrotoJavier, MazzeoFilomena, MengChangting, MeyerChristian, MichelDayana, MulcahyMary F, NapolitanoAndrea, NicholasGarth, OkunoScott, PenelNicolas, PhilipTony, Piperno-NeumannSophie, RazakAlbiruni Abdul, ReichardtPeter, RiedelRichard F, RyanChristopher, SchuetzeScott M, SchwartzGary K, ShachamSharon, ShahJatin J, SomaiahNeeta, StacchiottiSilvia, Valverde MoralesClaudia Maria, Van DomelenDane R, Van TineBrian A, VincenziBruno, WagnerAndrew J, WalkerChristopher J, YakobsonAlexander, ZickAviad, von MehrenMargaret

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selinexor improved progression-free survival in patients with advanced, refractory dedifferentiated liposarcoma.
Paper Details　
Original Abstract of the Article :
PURPOSE: Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS: S...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467680/

データ提供：米国国立医学図書館（NLM）

Selinexor: A Promising New Treatment for Dedifferentiated Liposarcoma

[Dedifferentiated liposarcoma (DD-LPS)] is a type of [soft tissue sarcoma] that can be difficult to treat. This research evaluates the [efficacy of selinexor] in patients with [advanced, metastatic DD-LPS]. The authors conducted a [phase II-III clinical trial] comparing [selinexor] to [placebo] in patients who had received [previous treatment with approved agents]. Their findings suggest that [selinexor] may offer [a significant improvement in progression-free survival] for patients with [refractory DD-LPS]. This study provides valuable insights into [the potential of selinexor] as a [new treatment option] for [DD-LPS].

Expanding the Treatment Arsenal for Dedifferentiated Liposarcoma

The study's findings offer [hope] for patients with [advanced, refractory DD-LPS]. The authors demonstrate that [selinexor] may have [a positive impact] on [progression-free survival] and [time to next treatment] in this patient population. This research highlights the importance of [ongoing research and development] to [identify new and effective treatments] for [challenging cancers].

Improving the Quality of Life for Cancer Patients

This study underscores the importance of [providing patients with effective treatment options] to [improve their quality of life] and [prolong their survival]. The authors emphasize the need for [continued research] to [develop new and effective therapies] for [cancers]. This research provides valuable information for [clinicians] and [patients] seeking to [manage DD-LPS].

Dr.Camel's Conclusion

Just as a camel endures the challenges of the desert, cancer patients face a difficult journey. This study offers a glimmer of hope for those battling dedifferentiated liposarcoma, highlighting the potential of selinexor to improve treatment outcomes. The findings inspire continued research to develop more effective therapies, providing patients with greater options and a brighter future.

Date :
  1. Date Completed 2022-07-29
  2. Date Revised 2023-03-23
Further Info :

Pubmed ID

35394800

DOI: Digital Object Identifier

PMC9467680

Related Literature

Article Analysis
・Side Effects of selinexor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.